Do We Have a Breakthrough Drug for Patients with Heart Failure?
Sensible Medicine
OCTOBER 14, 2024
Last Monday I wrote about one of the most positive drug trials in all of cardiology. In the RALES trial, the mineralocorticoid receptor antagonist (MRA) spironolactone substantially reduced death rates in patients with heart failure due to a weak heart. There were two big limitations to the RALES story. One was that the most common kind of heart failure now is heart failure with preserved heart function.
Let's personalize your content